outside of trials, this medicine should not be used
This usually involves a period of documented diet and exercise changes, sometimes supervised by a healthcare professional
The FDA has pointed to real problems with compounded GLP-1s: dosing errors from patients measuring their own doses out of multi-dose vials (some serious enough to require hospital care), counterfeit or mislabeled products sold online, and products that arrived warm or were stored incorrectly
In addition to residual cardiovascular risk despite aggressive LDL reduction, high costs limiting accessibility, and unresolved long-term safety concerns, past failures of HDL-directed therapies such as CETP inhibitors underscore the complexity of lipid biology
This process evaluates clinical and cost-effectiveness and involves a separate commissioning decision
Mounjaro (tirzepatide) stands out among GLP-1 receptor agonists due to its innovative dual-action mechanism that targets both GLP-1 and GIP receptors